Finally, after knowing the true capabilities of the HBV to interrupt the signals required for the cellular process called apoptosis, wherein cells commit suicide to avoid the virus from spreading, and armed with this knowledge, the Australian Scientists from Walter and Eliza Hall Institute researched on how to interrupt those signaling pathways employed by the HBV. Thus, they were able to discover a potential cancer drug called Birinapant which has the ability to allow infected cells to undergo normal apoptosis. The potential drug Birinapant, is combined with the anti-viral drug Entecavir and this combination therapy is tested on the animal infected with Hepatitis B. And impressively they were able to cure the virus 100% of the time and found out that this combination therapy is twice as fast as the potential drug can do. Led with this success the researchers are now planning to conduct human trials with this new therapy in December. Alongside with the human trials, the researchers will continue their study about this new therapy whether it can also treat chronic diseases such as herpes or dengue
Finally, after knowing the true capabilities of the HBV to interrupt the signals required for the cellular process called apoptosis, wherein cells commit suicide to avoid the virus from spreading, and armed with this knowledge, the Australian Scientists from Walter and Eliza Hall Institute researched on how to interrupt those signaling pathways employed by the HBV. Thus, they were able to discover a potential cancer drug called Birinapant which has the ability to allow infected cells to undergo normal apoptosis. The potential drug Birinapant, is combined with the anti-viral drug Entecavir and this combination therapy is tested on the animal infected with Hepatitis B. And impressively they were able to cure the virus 100% of the time and found out that this combination therapy is twice as fast as the potential drug can do. Led with this success the researchers are now planning to conduct human trials with this new therapy in December. Alongside with the human trials, the researchers will continue their study about this new therapy whether it can also treat chronic diseases such as herpes or dengue